CYTH News and Press, Cyclo Therapeutics Inc. From 04/12/22

Cyclo Therapeutics Inc. (NASDAQ:CYTH) traded today at a new 52-week high of $17.60. This new high was reached on above average trading volume as 18.2 million shares traded hands, while the average 30-day volume is approximately 61,000 shares. Based on a current price of $2.95, Cyclo Ther...

The following slide deck was published by Cyclo Therapeutics, Inc. in conjunction with this event. For further details see: Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow

– Live video webcast with moderated fireside chat with members from the Cyclo Therapeutics management team and featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday, April 5 th at 1:00 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Ther...

– Collaboration with the University of the Witwatersrand, Johannesburg (“Wits”), represented by Wits Commercial Enterprise; a wholly-owned subsidiary of the University mandated to manage and commercialize the University’s Intellectual Property; expected to ...

- Live webcast fireside chat on Wednesday, March 30 th at 12:30 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines t...

Cyclo Therapeutics press release (NASDAQ:CYTH): FY GAAP EPS of -$2.24 misses by $0.36. Revenue of $1.58M (+75.6% Y/Y) misses by $0.48M. For further details see: Cyclo Therapeutics GAAP EPS of -$2.24 misses by $0.36, revenue of $1.58M misses by $0.48M

- Lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) continues to progress - Company advancing Trappsol ® Cyclo™ for the treatment of Alzheimer’s D...

Presentation with live video webcast on Wednesday, March 16 th at 3:20 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medi...

Because many receptors and factors lead to the onset and early progression of Alzheimer's disease, targeting any one of them only slightly slows down the progression of Alzheimer's in subgroups. Targeting intervening points between receptor overactivation and peroxynitrite formation, ...

Most treatments for Alzheimer's disease either lead to only temporary improvements in cognition or only minimally slow down the progression of the disease because they only inhibit peroxynitrite formation. Anavex 2-73 appears to almost stabilize Alzheimer's disease for long periods of...